<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04691284</url>
  </required_header>
  <id_info>
    <org_study_id>PROBIO - SK - 006</org_study_id>
    <nct_id>NCT04691284</nct_id>
  </id_info>
  <brief_title>Microbiome in Cancer Patients With High Dose Chemotherapy With Stem Cell Transplantation</brief_title>
  <acronym>SCTMICROBIOM</acronym>
  <official_title>Microbiome in Cancer Patients Undergoing High Dose Chemotherapy With Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute, Slovakia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Slovak Academy of Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute, Slovakia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Numerous in vitro and animal studies as well as growing number of clinical studies support&#xD;
      the important role of microbiome in carcinogenesis and cancer treatment. Detection of changes&#xD;
      in patients´ microbiome following hematopoietic cell transplantation/CAR-T cell therapy and&#xD;
      correlations with adverse transplant outcomes, mainly infectious complications, acute and&#xD;
      chronic GvHD, disease recurrence etc. could serve as predictive markers of immune recovery&#xD;
      and treatment response.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Currently, available findings coming mainly from allo-HSCT (hhematopoietic cell&#xD;
      transplantation) studies, link particular changes in microbiota with overall survival and&#xD;
      post-transplant disorders, especially GvHD. According to limited data, further evaluation of&#xD;
      associations between the alterations in microbiome composition and toxicities. Detail&#xD;
      investigation of both the microbiome and host immune system may help to find microbiome&#xD;
      markers useful for very early identification of patients at risk for major transplant-related&#xD;
      complications. This might bring the possibility to modulate the gut microbiota in patient´s&#xD;
      specific manner to achieve optimal therapeutic outcome and follow-up, while avoiding severe&#xD;
      post-transplant complications.&#xD;
&#xD;
      This is prospective, single center, non-randomized, hypothesis generating study. Patients&#xD;
      will be asked to provide a sample of blood, urine and stool. This blood will be used for&#xD;
      plasma and serum banking for further analysis, including micro RNA (miR) and chemokine&#xD;
      detection. Stool will be used for microbiome studies - isolation of total DNA/RNA and 16S&#xD;
      (RNA component of the small subunit of a prokaryotic ribosome) rRNA (ribosomal ribonucleic&#xD;
      acid) gene sequencing for bacterial taxonomic classification. Furthermore, metagenomic&#xD;
      sequencing and subsequent taxonomic and functional classification of microbial genes will be&#xD;
      used including characterization of potentially clinically relevant features of the microbiome&#xD;
      such as antibiotic resistance and microbial virulence factors.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2021</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Microbial changes in stool as measured by 16S rRNA gene sequencing in hematological cancer patients before, at time and after hematopoietic cell transplantation and CAR-T cell therapy</measure>
    <time_frame>100 days</time_frame>
    <description>Microbial changes of stool will be assessed before, at time and after hematopoietic cell transplantation and CAR-T cell therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To correlate microbial changes in stool as measured by 16S rRNA gene sequencing with the post-transplant complications in auto and allogeneic transplant settings (GvHD, diarrhea, infectious complications) and in CAR-T cell therapy</measure>
    <time_frame>100 days</time_frame>
    <description>To assess microbial changes with toxicity of therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To correlate microbial changes in stool as measured by 16S rRNA gene sequencing with the patients reported outcomes.</measure>
    <time_frame>100 days</time_frame>
    <description>To correlate microbial changes with the quality of life, spirituality, cognitive functions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To correlate microbial changes in stool as measured by 16S rRNA gene sequencing with the patients nutrition status</measure>
    <time_frame>100 days</time_frame>
    <description>To correlate microbial changes with the patients nutrition.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Hematologic Neoplasms</condition>
  <arm_group>
    <arm_group_label>Observational arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be asked to provide a sample of blood, urine and stool. This blood will be used for plasma and serum banking for further analysis, including miR and chemokine detection. Stool will be used for microbiome studies - isolation of total DNA/RNA and 16S rRNA gene sequencing for bacterial taxonomic classification. Furthermore, metagenomic sequencing and subsequent taxonomic and functional classification of microbial genes will be used. Moreover, we might be able to characterized potentially clinically relevant features of the microbiome such as antibiotic resistance and microbial virulence factors.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood, urine and stool sampling</intervention_name>
    <description>Sampling of blood and urine for miR and chemokine detection. Sampling of stool for for microbiome studies.</description>
    <arm_group_label>Observational arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  signed written informed consent&#xD;
&#xD;
          -  aged 18 years or older&#xD;
&#xD;
          -  patients planned to be treated by high-dose chemotherapy and hematopoietic cell&#xD;
             transplantation or by CAR-T cell therapy in National Cancer Institute, Slovakia&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - patients not-matching inclusion criteria&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luboš Drgoňa, Assoc. Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>National Cancer Institute, Slovakia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michal Mego, prof.</last_name>
    <role>Study Chair</role>
    <affiliation>National Cancer Institute, Slovakia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Barbora Kašperová, MD</last_name>
    <phone>+421-2-59378272</phone>
    <email>barbora.kasperova@nou.sk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sona Ciernikova, PhD</last_name>
    <phone>+421-2-59378273</phone>
    <email>sona.ciernikova@savba.sk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Cancer Institute</name>
      <address>
        <city>Bratislava</city>
        <zip>83310</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniela Svetlovska</last_name>
      <phone>+421259378</phone>
      <phone_ext>592</phone_ext>
      <email>daniela.svetlovska@nou.sk</email>
    </contact>
    <contact_backup>
      <last_name>Barbora Kašperova, MD</last_name>
      <phone>+421259378</phone>
      <phone_ext>272</phone_ext>
      <email>barbora.kasperova@nou.sk</email>
    </contact_backup>
    <investigator>
      <last_name>Luboš Drgoňa, Assoc. Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michal Mego, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Soňa Čiernikova, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Barbora Kašperová, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Slovakia</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>December 19, 2020</study_first_submitted>
  <study_first_submitted_qc>December 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 31, 2020</study_first_posted>
  <last_update_submitted>March 2, 2021</last_update_submitted>
  <last_update_submitted_qc>March 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>microbiome</keyword>
  <keyword>high dose chemotherapy</keyword>
  <keyword>stem cell transplantation</keyword>
  <keyword>CAR-T cell</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

